Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferumoxytol extension for iron deficiency anemia
NCT01114217Phase 3Completed
- Sponsor
- AMAG Pharmaceuticals, Inc.
- Start
- Jul 2010
- Primary completion
- Sep 2012
- Modality
- Nanoparticles, Small Molecules
- Countries
- 6
01
Overview
Phase 3, open-label, single-arm trial of ferumoxytol in iron deficiency anemia (IDA), sponsored by AMAG Pharmaceuticals, Inc. Primary endpoint: Mean Change In Hemoglobin From TP Baseline To TP Week 5 Following The First Course Of Ferumoxytol. Started Jul 2010; status: completed.
02
Drugs
ferumoxytol
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT01114217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01114217.